Surgical treatment for stage III N2 non-small cell lung cancer.
- Author:
Siyu WANG
1
;
Yilong WU
;
Tiehua RONG
;
Zhifan HUANG
;
Wei OU
Author Information
- Publication Type:Journal Article
- MeSH: Aged; Carcinoma, Non-Small-Cell Lung; diagnosis; mortality; secondary; surgery; Female; Humans; Lung Neoplasms; diagnosis; mortality; pathology; surgery; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate
- From: Chinese Journal of Oncology 2002;24(6):605-607
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the survival and prognostic factors of stage III N2 non-small cell lung cancer (NSCLC) after surgical treatment.
METHODS266 patients with stage III N2 NSCLC underwent operation from 1982 to 1996, with the 5-year survival rate compared with those of stage N0 and N1 patients who received operation in the same period. Histological classification, number of positive nodes, location and extent of mediastinal lymph node involvement, T primary tumor status, complete or incomplete operation, the procedure of operation were univariately and multivariately analyzed to determine their impact on the 5-year survival.
RESULTSThe 5-year survival rate of patients with stage III N2 non-small lung cancer after surgical treatment was 17.3%, which was significant lower than those with N0 (51.4%) and N1 (30.4%). Four prognostic factors significantly influenced the outcome: number of positive nodes, location and extent of mediastinal lymph node involvement, T primary tumor status and complete resection of the tumor.
CONCLUSIONPatients with stage III N2 NSCLC are candidates for surgical treatment if they have evidence of limited mediastinal lymph node metastasis and prospects of complete resection.
